Insmed (INSM) Operating Income (2010 - 2026)
Insmed (INSM) posted quarterly Operating Income of -$153.3 million for Q1 2026, up 38.21% year-over-year from -$110.9 million in Q1 2025, and up 52.05% quarter-over-quarter from -$319.7 million in Q4 2025.
Insmed (INSM) Operating Income (2010 - 2026) Analysis & Trends
Insmed's Operating Income history runs 17 years deep, the most recent figure standing at -$153.3 million for Q1 2026.
- In Q1 2026, Operating Income rose 38.21% year-over-year to -$153.3 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 17.44% YoY), while the FY2025 annual figure was -$1.2 billion, down 41.96% from the prior year.
- Operating Income for Q1 2026 stood at -$153.3 million, up from -$319.7 million in the prior quarter.
- The five-year high for Operating Income was -$88.3 million in Q2 2022, with the low at -$366.0 million in Q3 2025.
- The 5-year median for Operating Income is -$178.3 million (2023), against an average of -$202.7 million.
- The sharpest annual moves came in 2023 and 2026: Operating Income sank 166.69% in 2023, then surged 38.21% in 2026.
- Insmed's Operating Income stood at -$151.5 million in 2022, then decreased by 17.69% to -$178.3 million in 2023, then decreased by 29.25% to -$230.4 million in 2024, then tumbled by 38.77% to -$319.7 million in 2025, then jumped by 52.05% to -$153.3 million in 2026.
- Business Quant data shows INSM's Operating Income at -$153.3 million in Q1 2026, -$319.7 million in Q4 2025, and -$366.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -365.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.55 Mn |
| Mar 31, 2026 | -153.32 Mn |
| Dec 31, 2025 | -319.75 Mn |
| Sep 30, 2025 | -366.01 Mn |
| Jun 30, 2025 | -312.88 Mn |
| Mar 31, 2025 | -248.14 Mn |
| Dec 31, 2024 | -230.41 Mn |
| Sep 30, 2024 | -213.43 Mn |
| Jun 30, 2024 | -288.90 Mn |
| Mar 31, 2024 | -145.51 Mn |
| Dec 31, 2023 | -178.27 Mn |
| Sep 30, 2023 | -147.67 Mn |
| Jun 30, 2023 | -235.53 Mn |
| Mar 31, 2023 | -148.16 Mn |
| Dec 31, 2022 | -151.48 Mn |
| Sep 30, 2022 | -127.70 Mn |
| Jun 30, 2022 | -88.32 Mn |
| Mar 31, 2022 | -89.83 Mn |
| Dec 31, 2021 | -99.08 Mn |
| Sep 30, 2021 | -103.62 Mn |